SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research Company (SPARC) has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.

The company has reported a net profit at Rs 1,760.70 crore for the quarter under review as compared to a net loss of Rs 60.98 crore for the same quarter in the previous year. The total income of the company has increased by many folds at Rs 1,855.02 crore for Q4FY26 as compared to Rs 27.19 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported a net profit at Rs 1,761.34 crore for the fourth quarter ended March 31, 2026 as compared to a net loss of Rs 59.77 crore for the same quarter in the previous year. The total income of the company increased by many folds at Rs 1,855.02 crore for Q4FY26 as compared to Rs 27.19 crore for the corresponding quarter previous year.

For the year ended March 31, 2026, the company has reported a net profit at Rs 1,552.13 crore as compared to a net loss of Rs 345.22 crore for the previous year. The total income of the company has increased by many folds at Rs 1,890.00 crore for year under review as compared to Rs 73.56 crore for year ended March 31, 2025.

For the year ended March 31, 2026, on the consolidated basis, the company has reported a net profit at Rs 1,553.20 crore as compared to a net loss of Rs 342.51 crore for the previous year. The total income of the company increased by many folds at Rs 1,890.12 crore for year under review as compared to Rs 73.56 crore for year ended March 31, 2025.

Sun Pharma Adv. Res Share Price

223.40 19.40 (9.51%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 458.60
Indegene 511.20
CMS Info Systems 296.90
JITF Infralogistics 297.85
Sagility 40.48
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: